Watchlist 2023-03-08 $FCEL $VET $CLNN $ASAN SPY - relatively flat this morning after two days of selling strength from Powell's hawkish testimony. Late in the session we had a ripping rally which quickly corrected to the downside in the after hours. To me this means that it flushed out some late shorts but the bears were still in control. Leaning slightly bearish for the day but not expecting any large moves as we put in a decent range over the last week and investors will we waiting on the payroll numbers Friday at 8:30 ET.
FCEL - Fiscal Q1 Loss Narrows, Revenue Increases; Shares Rise. If consolidation happens near the breakout pivot level 3.60, interested in a long with room to 3.85, has moved 1.3 ATRs in the PM and gapping over the last two weeks of trading. There was a Sutu rev H&S patter around the 3.10s which is a great indicator the name is ready to trade higher with this positive catalyst.
VET - Fiscal Q1 Loss Narrows, Revenue Increases; Shares Rise. National Bank sets price target to $29.
This is not an A+ trade as we have declining MAs and have only made a short base. However, for a very short term trade there is potential to the upside with the first good news catalyst and a PD red bar fake-out that will catch sellers off guard and flushed out some buyers. If it ranges for a few min near 14.26, there is a potential long with room to 14.80
CLNN - adds 16% after new data for lead asset in ALS study. Gapping over a clear range at 1.30 - this will be terrific gap and go support if we can get it. Else, looking for break above the 1.60 PM high and High vol node for room to 2.00 while taking profit on the way.
ASAN - stock soars 24% as software company says path to profitability is improving. Judging from the price action grinding higher up to earnings, this seems like a time for some profit taking, also judging from the PM sequential pullback. Key resistance is 22.30, 200 MA and the PM high vol node. Looking from pullback from scalp longs and failed follow through for shorts if we get extended.
CLNN trade ideas
CLNN | Lets Get It | Extremely OversoldClene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.